Carole Durot1, Sébastien Mulé2, Philippe Soyer3, Aude Marchal4, Florent Grange5, Christine Hoeffel6,7. 1. Department of Radiology, Reims University Hospital, 45 rue Cognacq-jay, 51092, Reims, France. cdurot@chu-reims.fr. 2. Department of Radiology, Henri Mondor University Hospital, Créteil, France. 3. Department of Radiology, Cochin University Hospital, Paris, France. 4. Department of Biopathology, Reims University Hospital, Reims, France. 5. Department of Dermatology, Reims University Hospital, Reims, France. 6. Department of Radiology, Reims University Hospital, 45 rue Cognacq-jay, 51092, Reims, France. 7. CRESTIC, University of Reims Champagne-Ardenne, Reims, France.
Abstract
PURPOSE: To determine whether texture analysis features on pretreatment contrast-enhanced computed tomography (CT) images can predict overall survival (OS) and progression-free survival (PFS) in patients with metastatic malignant melanoma (MM) treated with an anti-PD-1 monoclonal antibody, pembrolizumab. MATERIALS AND METHODS: This institutional-approved retrospective study included 31 patients with metastatic MM treated with pembrolizumab. Texture analysis of 74 metastatic lesions was performed on CT scanners obtained within 1 month before treatment. Mean gray-level, entropy, kurtosis, skewness, and standard deviation values were derived from the pixel distribution histogram before and after spatial filtration at different anatomic scales, ranging from fine to coarse. Lasso penalized Cox regression analyses were performed to identify independent predictors of OS and PFS. RESULTS: Median OS and PFS were 357 days (range 42-1355) and 99 days (range 35-1185), respectively. Skewness at coarse texture scale (SSF = 6; HR (CI 95%) = 6.017 (1.39, 26.056), p = 0.016), Response evaluation criteria in solid tumors (RECIST) conclusion (HR (CI 95%) = 3.41 (1.17, 9.89), p = 0.024), and body weight (HR (CI 95%) = 0.96 (0.92, 0.995), p = 0.026) were independent predictors of OS. Skewness at coarse texture scale (SSF = 6; HR (CI 95%) = 4.55 (1.46, 14.13), p = 0.0089) and RECIST conclusion (HR (CI 95%) = 10.63 (3.11, 36.29), p = 0.00016) were independent predictors of PFS. Skewness values above - 0.55 at coarse texture scale were significantly associated with both lower OS and lower PFS after administration of pembrolizumab. CONCLUSION: Pretreatment CT texture analysis-derived tumor skewness may act as predictive biomarker of OS and PFS in patients with metastatic MM treated with pembrolizumab. KEY POINTS: • Pretreatment skewness at coarse texture scale in metastases from malignant melanoma was an independent predictor of overall survival and progression-free survival. • Skewness values above -0.55 at coarse texture scale were significantly associated with both lower OS and lower PFS after administration of pembrolizumab. • In patients with metastatic MM, texture analysis performed on pretreatment CT may act as a useful tool to select the best candidates for pembrolizumab therapy.
PURPOSE: To determine whether texture analysis features on pretreatment contrast-enhanced computed tomography (CT) images can predict overall survival (OS) and progression-free survival (PFS) in patients with metastatic malignant melanoma (MM) treated with an anti-PD-1 monoclonal antibody, pembrolizumab. MATERIALS AND METHODS: This institutional-approved retrospective study included 31 patients with metastatic MM treated with pembrolizumab. Texture analysis of 74 metastatic lesions was performed on CT scanners obtained within 1 month before treatment. Mean gray-level, entropy, kurtosis, skewness, and standard deviation values were derived from the pixel distribution histogram before and after spatial filtration at different anatomic scales, ranging from fine to coarse. Lasso penalized Cox regression analyses were performed to identify independent predictors of OS and PFS. RESULTS: Median OS and PFS were 357 days (range 42-1355) and 99 days (range 35-1185), respectively. Skewness at coarse texture scale (SSF = 6; HR (CI 95%) = 6.017 (1.39, 26.056), p = 0.016), Response evaluation criteria in solid tumors (RECIST) conclusion (HR (CI 95%) = 3.41 (1.17, 9.89), p = 0.024), and body weight (HR (CI 95%) = 0.96 (0.92, 0.995), p = 0.026) were independent predictors of OS. Skewness at coarse texture scale (SSF = 6; HR (CI 95%) = 4.55 (1.46, 14.13), p = 0.0089) and RECIST conclusion (HR (CI 95%) = 10.63 (3.11, 36.29), p = 0.00016) were independent predictors of PFS. Skewness values above - 0.55 at coarse texture scale were significantly associated with both lower OS and lower PFS after administration of pembrolizumab. CONCLUSION: Pretreatment CT texture analysis-derived tumor skewness may act as predictive biomarker of OS and PFS in patients with metastatic MM treated with pembrolizumab. KEY POINTS: • Pretreatment skewness at coarse texture scale in metastases from malignant melanoma was an independent predictor of overall survival and progression-free survival. • Skewness values above -0.55 at coarse texture scale were significantly associated with both lower OS and lower PFS after administration of pembrolizumab. • In patients with metastatic MM, texture analysis performed on pretreatment CT may act as a useful tool to select the best candidates for pembrolizumab therapy.
Authors: Mizuki Nishino; Jyothi P Jagannathan; Nikhil H Ramaiya; Annick D Van den Abbeele Journal: AJR Am J Roentgenol Date: 2010-08 Impact factor: 3.959
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Kenneth A Miles; Balaji Ganeshan; Matthew R Griffiths; Rupert C D Young; Christopher R Chatwin Journal: Radiology Date: 2009-01-22 Impact factor: 11.105
Authors: Felix Peisen; Annika Hänsch; Alessa Hering; Andreas S Brendlin; Saif Afat; Konstantin Nikolaou; Sergios Gatidis; Thomas Eigentler; Teresa Amaral; Jan H Moltz; Ahmed E Othman Journal: Cancers (Basel) Date: 2022-06-17 Impact factor: 6.575
Authors: Balaji Ganeshan; Kenneth Miles; Asim Afaq; Shonit Punwani; Manuel Rodriguez; Simon Wan; Darren Walls; Luke Hoy; Saif Khan; Raymond Endozo; Robert Shortman; John Hoath; Aman Bhargava; Matthew Hanson; Daren Francis; Tan Arulampalam; Sanjay Dindyal; Shih-Hsin Chen; Tony Ng; Ashley Groves Journal: Cancers (Basel) Date: 2021-05-31 Impact factor: 6.639